Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

Revenue projections:

Revenue projections for SANOFI
Revenue projections for SANOFI

With SANOFI's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 1.567000
forwardPE 31.334913
debtToEquity 2.243000
earningsGrowth -0.337000
revenueGrowth -0.258000
grossMargins 0.506160
operatingMargins 0.210720
trailingEps 136.280000
forwardEps 203.770000

SANOFI's current ratio being 1.567 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that SANOFI can meet its financial obligations with ease.
With both earnings and revenue growth in low territory, SANOFI is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
Sanofi India Limited's positive gross and operating margins suggest the company is performing profitably. These margins reflect efficient cost management and strong revenue generation, signaling healthy financial performance and operational effectiveness.
Sanofi India Limited's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that Sanofi India Limited is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for SANOFI
Price projections for SANOFI

Sanofi India Limited's price projections have been revised downward over time, reflecting a shift in sentiment among analysts. The steady decline in projections points to a more cautious outlook on the company's future performance.

Recommendation changes over time:

Recommendations trend for SANOFI
Recommendations trend for SANOFI


Analysts have shown a buy bias for SANOFI, marking it as a favorable investment option. This could inspire investors to see SANOFI as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.